However, when compared to another MEK inhibitor, selumetinib (AZD6244, ARRY-142886), which was recently approved to treat children’s NF-1-related symptomatic, inoperable pNFs [43], the capacity of tumor amelioration is barely satisfactory with the ORR of 44.2% versus 73.8% [44]. Here, MAP2K7 is linked to neoplasm.